Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 950 of 994 entries
View as:

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

Phase: N/A Priority: Normal
NCT ID: NCT01232283 Org: User:
Start: 11/22/10 End: 11/30/16 Due: 11/30/17

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

Phase: N/A Priority: Normal
NCT ID: NCT04521231 Org: User:
Start: 01/04/21 End: 05/25/29 Due: 05/25/30

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Phase: N/A Priority: Normal
NCT ID: NCT03852472 Org: User:
Start: 12/21/18 End: 03/09/21 Due: 03/09/22

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01970488 Org: User:
Start: 10/18/13 End: 03/18/15 Due: 03/18/16

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06438263 Org: User:
Start: 08/06/24 End: 05/03/25 Due: 05/03/26

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

Phase: N/A Priority: Normal
NCT ID: NCT01949532 Org: User:
Start: 01/31/14 End: 01/31/17 Due: 01/31/18

Pediatric Chronic Kidney Disease Safety and Efficacy

Phase: N/A Priority: Normal
NCT ID: NCT01277510 Org: User:
Start: 06/28/11 End: - Due: -

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Phase: N/A Priority: Normal
NCT ID: NCT06229145 Org: User:
Start: 03/18/24 End: 05/18/26 Due: 05/18/27

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT06004934 Org: User:
Start: 04/17/18 End: 09/18/18 Due: 09/18/19

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Phase: N/A Priority: Normal
NCT ID: NCT06987539 Org: User:
Start: 08/29/25 End: 01/04/30 Due: 01/04/31

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

Phase: N/A Priority: Normal
NCT ID: NCT06468826 Org: User:
Start: 07/11/24 End: 10/05/24 Due: 10/05/25

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03809663 Org: User:
Start: 03/15/19 End: 12/22/20 Due: 12/22/21

Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02588534 Org: User:
Start: 08/31/04 End: 10/31/04 Due: 10/31/05

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00111774 Org: User:
Start: 03/31/02 End: - Due: -

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase: N/A Priority: Normal
NCT ID: NCT04631601 Org: User:
Start: 01/15/21 End: 10/23/23 Due: 10/23/24

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03859427 Org: User:
Start: 05/08/19 End: 03/31/23 Due: 03/31/24

Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01137565 Org: User:
Start: 06/30/10 End: 01/31/11 Due: 01/31/12

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Phase: N/A Priority: Normal
NCT ID: NCT00104650 Org: User:
Start: 01/31/05 End: 03/31/10 Due: 03/31/11

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00135317 Org: User:
Start: 11/30/04 End: - Due: -

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02072863 Org: User:
Start: 01/31/14 End: 09/30/15 Due: 09/30/16

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00992459 Org: User:
Start: 10/31/09 End: 09/30/10 Due: 09/30/11

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT00436995 Org: User:
Start: 04/30/06 End: 12/31/08 Due: 12/31/09

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00327119 Org: User:
Start: 04/30/06 End: - Due: -

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02274792 Org: User:
Start: 01/31/15 End: 11/30/15 Due: 11/30/16

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02366195 Org: User:
Start: 04/07/15 End: 12/25/20 Due: 12/25/21